CLB PE Ratio & Valuation, Is CLB Overvalued
Core Laboratories Inc (CLB) is currently in the "Fair zone" with a forward P/E ratio of 19.76, which is lower than its five-year average of 25.04. Its fair price is estimated to be between $16.10 and $28.19 based on relative valuation. The article also details CLB's P/B ratio, FCF yield, and compares its P/S ratio to competitors.
Core Laboratories (NYSE:CLB) Stock Price Passes Above 200-Day Moving Average - Here's Why
Core Laboratories (NYSE:CLB) stock recently traded above its 200-day moving average, reaching $16.70. The company beat Q4 earnings estimates with $0.21 EPS and $138.3M in revenue, and issued Q1 2026 EPS guidance of $0.110–0.150. While analysts have a "Hold" rating with a $12.50 target, institutional investors, including Ariel and Goldman Sachs, significantly increased their stakes, now owning nearly 97.8% of outstanding shares.
Core Laboratories Hits Day High with Strong 7.25% Intraday Surge
Core Laboratories, Inc. experienced a 7.25% intraday surge, reaching a high of USD 17.63, and has outperformed the S&P 500 over the past week and year. Despite this recent positive performance, the oil industry company faces challenges with longer-term stock declines and a significant drop in profits over the last year. The company maintains strong institutional ownership and currently has a P/E ratio of 28.00 and a dividend yield of 38.11%.
Precision Trading with Core Laboratories Inc. (CLB) Risk Zones
This article analyzes Core Laboratories Inc. (CLB) using AI-generated signals for precision trading, identifying strong sentiment and specific risk zones. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with defined entry, target, and stop-loss levels. The analysis provides multi-timeframe insights, highlighting resistance and support levels to optimize trading decisions.
Vanguard (NYSE: CLB) amendment shows 0 beneficial shares after realignment
The Vanguard Group filed an amendment to its Schedule 13G/A report, indicating 0 beneficial shares of Core Laboratories Inc. common stock. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries began reporting beneficial ownership separately. The filing clarifies that Vanguard itself no longer directly owns or is deemed to own shares in CLB under this realignment.
Middle East Tensions Impact Core Laboratories' First Quarter Forecast
Core Laboratories Inc. has revised its Q1 2026 financial guidance downwards due to escalating geopolitical instability in the Middle East, which has caused operational hurdles, project delays, and supply chain issues. The company now expects lower revenues, operating income, and earnings per share. Despite the negative short-term outlook, Core Laboratories, an oilfield services provider with global operations, continues to monitor the situation, recognizing the high degree of uncertainty impacting energy service providers in volatile regions.
Middle East Tensions Impact Core Laboratories' First Quarter Forecast
Core Laboratories Inc. (CLB) has lowered its financial outlook for the first quarter of 2026 due to growing geopolitical instability in the Middle East, leading to operational hurdles and project delays. The company now projects lower revenues, operating income, and earnings per share. While the short-term forecast is impacted, Core Laboratories maintains a positive long-term outlook despite the challenges for its Reservoir Description and Production Enhancement segments.
Core Laboratories Inc stock faces pressure amid oilfield services slowdown and Q4 earnings anticipat
Core Laboratories Inc (NL0015000CZ2) is experiencing stock pressure due to a slowdown in the oilfield services sector, marked by declining US rig counts and crude price volatility. Investors are anticipating its Q4 2025 earnings, with focus on margin resilience and international backlog strength, particularly given the company's strong position in reservoir analysis and production enhancement. Despite challenges, the company's low debt and attractive dividend yield offer some stability.
Core Laboratories Inc stock faces pressure amid oilfield services slowdown and Q4 earnings anticipation
Core Laboratories Inc is experiencing stock pressure due to a slowdown in the oilfield services sector, marked by declining US rig counts and volatile crude prices. The company, which specializes in oil and gas reservoir analysis, is preparing for its Q4 earnings report, with investors focusing on margin resilience and international backlog strength. Despite the challenges, Core Lab maintains steady operations, a low debt profile, and an attractive dividend yield, leveraging its technology in reservoir optimization and diversification into international projects.
Middle East Conflict Weighs On Core Laboratories' Q1 Outlook
Core Laboratories (CLB) has revised its first-quarter 2026 financial guidance downwards due to escalating geopolitical tensions in the Middle East, which are causing significant operational disruptions, project delays, and supply chain issues. The conflict is particularly impacting its Reservoir Description segment, leading to reduced revenue and earnings expectations. The company is actively managing the situation, prioritizing employee safety, and monitoring developments, though near-term visibility remains limited.
Middle East Conflict Weighs On Core Laboratories' Q1 Outlook
Core Laboratories (CLB) has lowered its first-quarter 2026 financial guidance due to escalating geopolitical tensions in the Middle East, which have caused operational disruptions, project delays, and supply chain issues. The company's Reservoir Description segment is particularly affected, while Production Enhancement shows more resilience. CLB's revised outlook reflects significantly reduced revenue, operating income, and earnings per share expectations, underscoring the material impact of regional instability on energy service providers.
Core Laboratories (CLB) Margin Slippage In Q4 2025 Tests Long Term Earnings Growth Narrative
Core Laboratories (CLB) reported Q4 2025 revenue of US$138.3 million and basic EPS of US$0.11, with net income of US$4.9 million. The company's net profit margin for the trailing year settled at 5.6%, a slight decrease from 6.0% in the prior year, despite a five-year earnings growth of 28.7%. This margin slippage and the stock's valuation, trading at a 24.4x P/E but significantly above its DCF fair value of US$3.69, are challenging the long-term earnings growth narrative, prompting investors to scrutinize the consistency of its profitability.
Core Laboratories (NYSE: CLB) trims Q1 2026 guidance amid Middle East turmoil
Core Laboratories (NYSE: CLB) has significantly lowered its first-quarter 2026 financial guidance due to the escalating Middle East conflict. The company now anticipates revenue between $119 million and $123 million, with adjusted operating income ranging from $5.7 million to $7.1 million, and EPS between $0.05 and $0.07. This downward revision is attributed to client-driven project delays, travel restrictions, supply-chain disruptions, and damage to regional oil infrastructure, primarily impacting its Reservoir Description segment.
Core Laboratories (NYSE:CLB) Shares Gap Down - Here's Why
Core Laboratories (NYSE:CLB) shares gapped down about 4.3% on Tuesday, opening at $16.05 after closing at $16.87. This occurred despite the company beating quarterly earnings estimates with $0.21 EPS and $138.26 million in revenue, and providing Q1 2026 guidance between $0.110-$0.150 EPS. Analysts currently have a consensus "Hold" rating on the stock with a target price of $12.50.
Here’s Why Maintaining a Hold Position Is Suitable for Core Laboratories Shares at This Time
Core Laboratories (CLB) specializes in oilfield services, focusing on reservoir analysis and production enhancement, and currently trades at a discount compared to its sub-industry average P/E ratio. While CLB benefits from technological advantages, international expansion, and high-margin services, it faces short-term risks including Middle East instability, declining U.S. onshore activity, and commodity price volatility. Given these factors, analysts suggest maintaining a "Hold" position and waiting for a more favorable entry point.
Core Laboratories Sees Q1 Adj EPS $0.05-$0.07...
Core Laboratories (NYSE:CLB) has released its Q1 guidance, projecting adjusted EPS between $0.05 and $0.07, which is below the estimated $0.14. The company also lowered its Q1 sales guidance from $124.00 million-$130.00 million to $119.00 million-$123.00 million, falling short of the $128.29 million estimate. This headline-only article highlights real-time intelligence used by traders.
Stocks to Watch: Core Laboratories, Bark
This article identifies Core Laboratories and Bark as stocks to watch.
Core Laboratories cuts Q1 2026 guidance on Middle East conflict
Core Laboratories Inc. (CLB) has lowered its Q1 2026 financial guidance significantly due to geopolitical instability in the Middle East, leading to project delays and disruptions. Despite these near-term challenges, InvestingPro analysis suggests the stock remains undervalued. The company, however, maintains strong financial liquidity and a history of dividend payments, with its Reservoir Description segment being more affected than Production Enhancement.
Core Laboratories Expects Q1 2026 Revenue An...
Core Laboratories (NYSE:CLB) has revised its guidance for the first quarter of 2026, anticipating revenue and earnings per share to be below its previously issued guidance from February 4, 2026. The company now expects Q1 EPS to be between $0.05-$0.07, and revenue is projected to range from $119 million to $123 million. This update indicates a downturn from previous expectations.
Core Laboratories Cuts Q1 2026 Guidance Amid Mideast Turmoil
Core Laboratories (CLB) has significantly revised its first-quarter 2026 earnings guidance downwards due to the ongoing geopolitical conflict in the Middle East, citing client-driven project delays, travel constraints, and supply-chain disruptions. The company now forecasts Q1 2026 revenue between $119 million and $123 million and earnings per share of $0.05 to $0.07. The impact is particularly felt in its Reservoir Description segment and affects the shipment of energetics products for Production Enhancement, highlighting the substantial operational and logistical risks in the region.
Middle East conflict hits Core Lab as project delays cut Q1 outlook
Core Laboratories (NYSE:CLB) has revised its first-quarter 2026 financial guidance downwards due to the ongoing Middle East conflict, citing client-driven project delays, travel restrictions, and supply-chain disruptions. The company now expects lower revenue, operating income, and EPS, with its Reservoir Description segment being most affected. An earnings webcast is scheduled for April 30, 2026, to discuss these results further.
Core Laboratories 10-K: $526.5M Revenue, $0.65 Diluted EPS
Core Laboratories reported full-year revenue of $526.5 million and diluted earnings per share of $0.65, showing flat revenue performance and a slight decline in net income compared to the previous year. The company saw increased services revenue, especially internationally, which offset a decline in product sales, and is focusing on well-completion diagnostics, crude assay services, and energy-transition areas. Management is monitoring geopolitical events and commodity prices as potential risks.
CWA Asset Management Group LLC Makes New Investment in Core Laboratories Inc. $CLB
CWA Asset Management Group LLC has made a new investment in Core Laboratories Inc. (NYSE:CLB), purchasing 622,453 shares valued at approximately $9.98 million during the fourth quarter. This acquisition represents 1.34% of Core Laboratories, further solidifying institutional ownership, which collectively stands at 97.81%. The financial news comes as Core Laboratories slightly beat Q4 earnings estimates and announced a small quarterly dividend, with analysts predicting a "Hold" rating for the stock.
Core Laboratories Revises Financials Following Tax Review ()
Core Laboratories has restated its 2025 financials due to a tax review related to insurance recoveries from a fire at its Aberdeen facility. While these revisions negatively impact net income and earnings per share, the company's underlying operational performance, including revenue and cash flow, remains unchanged. The adjustments clarify tax accounting and finalize a chapter of financial re-evaluation before the next reporting cycle.
Core Laboratories (NYSE: CLB) trims 2025 EPS after $4.2M tax adjustment
Core Laboratories (NYSE: CLB) has filed an amended report to correct its 2025 financial statements, increasing its estimated income tax expense by $4.2 million. This adjustment reduces diluted earnings per share by $0.09 but does not affect consolidated revenue, operating income, income before tax, or cash from operations. The changes stem from updated analyses of deferred tax assets and liabilities and the tax treatment of insurance proceeds from a facility fire.
Core Laboratories Inc. $CLB Shares Sold by Earnest Partners LLC
Earnest Partners LLC reduced its stake in Core Laboratories Inc. (NYSE:CLB) by 4.9% in the third quarter, selling 175,370 shares and retaining 3,427,659 shares valued at $42,366,000. Despite this, other institutional investors like Ariel Investments LLC and Disciplined Growth Investors Inc. MN increased their holdings. The company's stock currently has an average rating of "Hold" and a consensus price target of $12.50, following recent positive quarterly earnings and a declared dividend.
Core Laboratories Inc. Earnings and Revenue – DUS:HJ1
Core Laboratories Inc. (DUS:HJ1) reported earnings of 0.18 EUR per share, exceeding the 0.16 EUR estimate by 9.81%. The company's revenue reached 117.71M EUR, surpassing the estimated 112.50M EUR. For the upcoming quarter, analysts anticipate 0.11 EUR in earnings per share and 110.06M EUR in revenue.
Core Laboratories (NYSE:CLB) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?
Core Laboratories (NYSE:CLB) stock has crossed above its 200-day moving average, a technical momentum signal. Despite this, analyst sentiment remains cautious with a consensus "Hold" rating and a price target below its current trading price. The company slightly beat Q4 earnings estimates but provided conservative Q1 2026 guidance, and institutional investors hold a significant portion of its shares.
Debt to assets ratio of Core Laboratories Inc. – DUS:HJ1
This page provides financial data for Core Laboratories Inc. (DUS:HJ1) from the Dusseldorf Stock Exchange, specifically focusing on its debt-to-assets ratio. It presents a table with periods, values, and percentage changes related to this financial metric. The content indicates that the market is closed and no trades have occurred for this stock.
Total equity of Core Laboratories Inc. – DUS:HJ1
This article provides financial data specifically on the total equity of Core Laboratories Inc., traded on the Dusseldorf Stock Exchange under the ticker HJ1. It indicates that the market is closed and presents a basic overview of its financial performance. The content is primarily a data point within a larger financial information platform.
Quick ratio of Core Laboratories Inc. – DUS:HJ1
The article focuses on the quick ratio of Core Laboratories Inc. (DUS:HJ1) as presented on TradingView. It briefly displays the stock's market status and mentions various data provisions from ICE Data Services, FactSet, and Quartr for financial information.
Core Laboratories (CLB) Gains on Sequential Revenue Growth and Solintec Acquisition
Core Laboratories Inc. (NYSE:CLB) saw increased trading activity and positive sentiment after reporting sequential revenue growth, improved operating income and EPS, and the acquisition of Brazil-based Solintec. While the Ariel Fund holds a positive view on CLB due to its global footprint and specialized services in energy development, the company is not among Insider Monkey's top 40 most popular stocks for hedge funds due to a preference for AI stocks with higher and faster return potential. Despite this, CLB has strengthened its financial position through debt reduction and capital returns.
Core Laboratories Eases Shareholder Threshold for Major Deals
Core Laboratories (CLB) has amended its bylaws to reduce the shareholder voting threshold for major corporate actions, such as mergers and change-in-control transactions, from a 66-2/3% supermajority to a simple majority. This change aims to streamline decision-making for strategic deals, potentially enhancing shareholder influence and increasing the company’s flexibility. TipRanks' AI Analyst, Spark, rates CLB as Neutral due to mixed financials and a somewhat expensive valuation despite a high dividend yield.
Core Laboratories (NYSE: CLB) cuts supermajority for merger votes
Core Laboratories (NYSE: CLB) has amended its bylaws to reduce the voting threshold for significant corporate actions, such as mergers and change in control transactions. The required shareholder approval has shifted from a 66-2/3% supermajority to a simple majority of 50% plus one vote, effective February 27, 2026. This change aims to simplify the procedural path for approving major deals, potentially impacting the balance between management and shareholder decision-making.
Core Laboratories Delays 2025 Annual 10-K Filing
Core Laboratories (CLB) has delayed its 2025 annual Form 10-K filing due to complex income tax accounting analyses across multiple jurisdictions and ongoing internal control evaluations. The company warns of potential non-cash tax adjustments and possible internal control weaknesses, though it confirms no disputes with auditors and continued SEC reporting compliance. The delay's exact length is uncertain, but management is working diligently to finalize the required reports.
Core Laboratories (CLB) delays 2025 10-K amid international tax, control review
Core Laboratories (CLB) has delayed filing its 2025 Annual Report on Form 10-K due to the need for additional time to complete international income tax accounting analyses and management's evaluation of internal controls. The company noted that this could result in a material, non-cash impact to income tax-related balances and a potential conclusion of a significant deficiency or material weakness in internal control over financial reporting. The delay is not attributed to any disagreements with its independent registered public accounting firm.
Core Laboratories (CLB) grants 7,526 performance share units to CAO Teo Sow Hang
Core Laboratories Inc. has granted 7,526 performance share units to its Chief Accounting Officer and Treasurer, Teo Sow Hang, on February 12, 2026. These units, with an exercise price of $0, are tied to underlying common stock and vest on December 31, 2028, based on a three-year performance period from January 1, 2026, to December 31, 2028. Vesting is contingent on Core Laboratories' Return on Invested Capital (ROIC) compared to its Bloomberg Peer Group, with potential payouts ranging from 100% to 200% of the target amount depending on ROIC percentile achievement.
Executive at Core Laboratories (NYSE: CLB) granted 33,490 performance shares
Core Laboratories Inc. granted SVP, General Counsel and Secretary Mark Damian Tattoli 33,490 performance shares on February 12, 2026. These are derivative equity awards with no cash exercise price, tied to a three-year performance period based on the company’s Return on Invested Capital versus a Bloomberg Peer Group. Vesting occurs on December 31, 2028, ranging from 50% to 175% of the target award, influenced by relative performance and a potential reduction if total shareholder return is negative.
[Form 4] Core Laboratories Inc. /DE/ Insider Trading Activity
Core Laboratories Inc.'s Chairman and CEO, Bruno Lawrence, was awarded 204,340 performance share units on February 12, 2026. These units, with an exercise price of $0, are designed to vest based on the company's Return on Invested Capital (ROIC) ranking within its Bloomberg Peer Group over a three-year performance period ending December 31, 2028. Vesting can range from 50% to 175% of the award, with a potential reduction if absolute total shareholder return is negative.
Core Labs Jumps 79% in 6 Months: Time to Buy or Stay on the Sidelines?
Core Laboratories Inc. (CLB) has seen a significant 79% stock increase in the past six months, outperforming its sub-industry and sector due to strong international demand, consistent shareholder returns, a robust balance sheet, and an asset-light business model. However, the company faces near-term headwinds from U.S. onshore activity, margin compression from tariffs and raw material costs, dependence on client success, and valuation concerns, leading Zacks to rate the stock as a "Hold." Investors are advised to wait for a more opportune entry point, while other related companies like TechnipFMC (FTI), Oceaneering International (OII), and USA Compression Partners (USAC) are rated as "Buy."
Disciplined Growth Investors boosts Core Laboratories (CLB) stake to 11.1%
Disciplined Growth Investors, an investment adviser, has increased its beneficial ownership in Core Laboratories (CLB) to 11.1% of outstanding common shares, as detailed in an amended Schedule 13G/A filing. As of December 31, 2025, the firm held 5,166,914 shares with sole dispositive power and significant voting power. This passive investment indicates the shares were acquired in the ordinary course of business, not for influencing control of the company.
Core Laboratories (NYSE: CLB) awards 33,490 performance shares to SVP
Core Laboratories (NYSE: CLB) has awarded 33,490 performance shares to its SVP, Gwendolyn Gresham, with an exercise price of $0. The award is tied to a three-year performance period from January 1, 2026, to December 31, 2028, and will vest based on the company's Return on Invested Capital (ROIC) compared to the Bloomberg Peer Group. Payout levels can range from 50% to 175% of the target award, with a potential reduction if the total shareholder return is negative.
Core Laboratories (NYSE:CLB) Shares Pass Above 200 Day Moving Average - Should You Sell?
Core Laboratories (NYSE:CLB) shares recently surpassed their 200-day moving average, trading at $18.5580 with a 200-day average of $14.71. The company reported better-than-expected earnings for the last quarter and announced a quarterly dividend. Analysts currently rate the stock as "Hold" with an average target price of $12.50.
Core Laboratories Q4 Earnings Beat Estimates, Expenses Increase Y/Y
Core Laboratories (CLB) reported fourth-quarter 2025 adjusted earnings of 21 cents per share, surpassing the Zacks Consensus Estimate, primarily due to strong performance in its Production Enhancement segment. Despite a year-over-year revenue increase of 7% to $138.3 million, total costs and expenses rose by 6.4%, and the company's Reservoir Description segment underperformed. CLB also provided an outlook for Q1 2026, anticipating revenue between $124 million and $130 million, with earnings per share projected to be between 11 and 15 cents.
Core Laboratories N.V. (NYSE:CLB) Q4 2025 Earnings Call Transcript
Core Laboratories N.V. (NYSE:CLB) announced its Q4 2025 earnings, with revenue up 3% quarter-over-quarter and 7% year-over-year, driven by strong international demand for proprietary technologies. The company emphasized its strategic plan focusing on technology investments, operational efficiency, and returning free cash to shareholders through dividends and share repurchases. Despite geopolitical conflicts and commodity price volatility, Core Lab maintains a constructive multi-year outlook, particularly for international and offshore exploration, while acknowledging a flattening of US onshore production growth.
Core Laboratories Q4 Earnings Beat Estimates, Expenses Increase Y/Y
Core Laboratories (CLB) reported Q4 2025 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 20 cents, largely due to strong performance in its Production Enhancement segment. Despite beating revenue estimates with $138.3 million, the company's bottom line decreased year-over-year due to increased expenses and a weaker Reservoir Description segment. Core Laboratories provided an outlook for Q1 2026, anticipating revenues between $124 million and $130 million, and discussed its strategy in a volatile market for oil and gas services.
Core Laboratories Q4 Earnings Beat Estimates, Expenses Increase Y/Y
Core Laboratories (CLB) reported Q4 2025 adjusted earnings of 21 cents per share, surpassing the Zacks Consensus Estimate of 20 cents, driven by strong performance in its Production Enhancement segment. Despite the beat, the bottom line saw a slight year-over-year decrease due to increased expenses and underperformance in the Reservoir Description segment. The company also announced a quarterly cash dividend and provided an outlook for Q1 and the full year 2026, anticipating continued growth in international demand despite some U.S. land market softness and tariff pressures.
Core Laboratories Stock Under Pressure: Is This Energy Services Veteran a Contrarian Buy or a Value
Core Laboratories (CLB) stock has recently experienced a modest slide, causing investors to question if it's a contrarian buy or a value trap, despite a solid year-over-year gain. The stock's performance reflects a mixed technical picture and cautious bearish sentiment, with analysts largely holding neutral stances. Its future trajectory will depend on capital allocation trends in the energy sector, crude oil prices, CLB's execution on cost control, and the growing commercial traction of its involvement in the energy transition.
Core Laboratories outlines Q1 2026 guidance of $124M–$130M revenue amid strong international demand and cost challenges
Core Laboratories (NYSE: CLB) announced its guidance for Q1 2026, projecting revenues between $124 million and $130 million. This outlook is driven by increasing international activity, particularly in the Eastern Hemisphere, which is expected to represent over half of the company's revenue for the first time in a decade. Despite strong demand, the company anticipates continued cost challenges related to labor and supply chain issues.
Core Lab (CLB) Q4 2025 Earnings Call Transcript
Core Laboratories (CLB) reported modest revenue growth in Q4 2025, driven by international demand and advanced technologies, despite geopolitical disruptions, tariffs, and weather challenges. The company emphasized its commitment to shareholder returns through dividends and share repurchases, while projecting a seasonal dip in Q1 2026. Management highlighted a long-term constructive outlook, focusing on international exploration and field development, cost discipline, capital allocation, and technological innovation.
